Acta Psychiatrica Scandinavica
April 16, 2025
Danica E. Johnson, Nelson B Rodrigues, Rodrigo B. Mansur et al.
Childhood trauma is a well‐established risk factor for major depressive disorder (MDD) and is often associated with attenuated response to conventional antidepressant therapies. Ketamine has emerged as an effective treatment for treatment‐resistant depression (TRD), but the impact of childhood trauma on its effectiveness remains unclear. Herein, we aimed to determine whether childhood trauma...
Frontiers in Psychiatry
April 15, 2025
Hao-Yan Li, Wen-jing Xu, Ya-Mei Wang et al.
Background Postoperative depression (POD) represents a serious complication in surgical patients, exacerbating morbidity and mortality rates while imposing a substantial economic burden on healthcare systems. Despite its widespread clinical use, the role of esketamine, an NMDA receptor antagonist with rapid antidepressant effects, remains understudied in perioperative settings. Therefore, we...
Biological Psychiatry
April 15, 2025
Mary L Woody, Rebecca Rohac, Iya Cooper et al.
1 citation
Ketamine is known for its rapid antidepressant effect, but its impact on affective information processing (including attentional bias [AB], a putative cognitive mechanism of depression) remains largely unexplored. We leveraged a novel measurement of AB and sought to 1) establish adequate test-retest reliability and validity among participants with depression prior to ketamine treatment and 2)...
International Journal of Molecular Sciences
April 10, 2025
Mădălina Iuliana Mușat, Ana-Maria Ifrim-Predoi, Smaranda Ioana Mitran et al.
5 citations
Non-alcoholic fatty liver disease (NAFLD) has been associated with depression and inadequate response to antidepressants. While ketamine has demonstrated efficacy in treating depression, its impact on pre-existing liver injury and depression remains unclear. This study aimed to evaluate the effects of ketamine treatment in a murine model of depression and liver damage, considering age-related...
Psychopharmacology Bulletin
April 8, 2025
Keming Gao, Buket Koparal, Evrim Bayrak Oruc et al.
99 citations
In this case report, we present a patient with treatment-resistant depression (TRD) and comorbid generalized anxiety disorder, eating disorder, post-traumatic stress disorder, and borderline personality disorder. Over a 10-year period, our case transitioned from adolescence to adulthood and received antidepressant monotherapy, adjunctive therapy with antipsychotics, lithium, or lamotrigine,...
Current Neuropharmacology
April 7, 2025
Marika Alborghetti, Luana Lionetto, Ginevra Lombardozzi et al.
1 citation
Esketamine is administered intranasally in combination with at least another antidepressant in patients with treatment-resistant depression. Some of these antidepressants might affect ketamine's pharmacokinetic profile by inhibiting cytochrome-P450 (CYP450) isoforms. Our aim was to establish how different types of combined antidepressants affect serum and salivary levels of esketamine at the...
Journal of Education Health and Sport
April 5, 2025
Joanna Dmochowska, Marcin Ciechański, Joanna Cieszkowska et al.
1 citation
Introduction: Depression, affecting 350 million people globally, is a leading cause of disability. Common symptoms include low mood, sadness, guilt, anxiety, and suicidalthoughts. Current treatments, mostly monoamine-based antidepressants, have limitations such as delayed effects and low efficacy, with over 60% of patients not achieving lasting remission. Ketamine, an NMDA antagonist, has shown...
Brain, behavior, and immunity
April 4, 2025
Manivel Rengasamy, Benjamin Panny, Zakary Hutchinson et al.
3 citations
Ketamine is a rapid-acting treatment for treatment-resistant depression (TRD), though mechanisms related to ketamine's effects remain unclear. Blood-based neurotrophic and inflammatory factors (NIFs; e.g., brain-derived neurotrophic factor, interleukin-6) have emerged as markers potentially linked to ketamine and ketamine treatment response. In this secondary analysis of a randomized controlled...
Clinical Neuropsychopharmacology and Addiction
April 2, 2025
Filippo Mazzoni, Giovanni Carnevale Miacca, Alessandro Guffant et al.
Case Report Esketamine in Geriatric Depression and Pseudodementia: A Case Study Filippo Mazzoni 1,2, Giovanni Carnevale Miacca 1,2, Alessandro Guffanti 1,2, Vassilis Martiadis 3, Benardo Maria Dell’Osso 4,5,6,7, Natascia Brondino 1,2 and Miriam Olivola 1,4 1 Department of Brain and Behavioural Sciences, University of Pavia, 27100 Pavia, Italy 2 Department of Mental Health and Addiction, ASST...
The British journal of psychiatry : the journal of mental science
April 2, 2025
Wei-Chen Lin, Li-Kai Cheng, Tung-Ping Su et al.
2 citations
Evidence suggests the crucial role of dysfunctional default mode (DMN), salience and frontoparietal (FPN) networks, collectively termed the triple network model, in the pathophysiology of treatment-resistant depression (TRD). Using the graph theory- and seed-based functional connectivity analyses, we attempted to elucidate the role of low-dose ketamine in the triple networks, namely the DMN,...